

# PRE-CONFERENCE PROGRAMME

## TUESDAY 20 SEPTEMBER 2022

08:30	09:00	Registration	Polo Zanotto Main Entrance
<b>Pre-Conference Course 1</b> Advanced signal detection			09:00 – 17:00 Room T3
<p>Signal detection is one of the main activities of Pharmacovigilance. The approach to signal generation, refinement, and confirmation has evolved over years, opening new frontiers of debate about the roles of different stakeholders in the process and the need for an implementation of regulatory frameworks, publication rules, and risk communication strategies. In 2021, the circumstances of the approval of COVID-19 vaccines were exceptional and provided an unprecedented challenge for signal detection that deserves to be studied in-depth. This one-day pre-conference course will illustrate the process of signal detection using a step-by-step approach, starting from basic elements and concluding with discussion on the most current challenges being faced.</p> <p><i><b>Chairs:</b> Marco Tuccori (University of Pisa, Italy) and Ugo Moretti (University of Verona, Italy)</i></p>			
09:00	10:00	<b>Fundamentals of signal detection for drugs and vaccines</b> <i>Eugene Van Puijenbroek (The Netherlands Pharmacovigilance Centre Lareb, Netherlands)</i>	
10:00	10:30	<b>Open source PV databases as sources for signal detection: strengths and limitations</b> <i>Ugo Moretti (University of Verona, Italy)</i>	
10:30	11:00	<b>Publishing signal detection analysis: quality criteria</b> <i>Francesco Salvo (University of Bordeaux, France)</i>	
11:00	11:15	<b>Coffee Break</b>	
11:15	12:00	<b>State of the art in signal detection – a regulatory perspective</b> <i>Phil Tregunno (Medicines and Healthcare products Regulatory Agency - MHRA, UK)</i>	
12:00	12:45	<b>Patients reporting and signal detection: strengths and limitations</b> <i>Linda Härmark (The Netherlands Pharmacovigilance Centre Lareb, Netherlands)</i>	
12:45	14:00	<b>Lunch break</b>	
14:00	14:45	<b>Causality and chance in recent pharmacovigilance signals of COVID-19 vaccines: what evidence for public health decisions?</b> <i>Bernard Bégaud (University of Bordeaux, France and chair of the EPIPHARE scientific committee)</i>	
14:45	15:30	<b>Signal detection using Pharma industry databases</b> <i>Maria Maddalena Lino (Pfizer, Italy)</i>	

15:30	15:45	<b>Coffee break</b>
15:45	16:15	<b>Signal detection for oncologic drugs</b> <i>Emanuel Raschi (University of Bologna, Italy)</i>
16:15	17:00	<b>Managing signal detection during crisis in Regulatory Agencies and Pharmacovigilance Regional Centers</b> <i>Pasquale Marchione (Agenzia Italiana del Farmaco (AIFA), Italy)</i>
19:30	21:00	<b>Welcome Reception – University of Verona, Cloister of San Francesco</b>

<b>Pre-Conference Course 2</b>		<b>09:00 – 12:45</b>
<b>Introduction to pharmacoepidemiology studies and their role in Pharmacovigilance</b>		<b>Room T2</b>
<p>The aim of this half-day course is to provide a basic understanding of the concepts and practice of pharmacoepidemiology. You will learn about the fundamentals of pharmacoepidemiology, its practical uses, and its limitations, as well as how pharmacoepidemiology and pharmacovigilance can be used together to inform medicines safety.</p> <p>By the end of the course, participants should be able to:</p> <ul style="list-style-type: none"> <li>• demonstrate an understanding of basic study designs commonly used in pharmacoepidemiology</li> <li>• gain an understanding of fundamental statistical concepts</li> <li>• be familiar with potential sources of error and the limitations of pharmacoepidemiological studies</li> <li>• understand how data from pharmacovigilance and pharmacoepidemiology can be synthesized into evidence of safety</li> </ul> <p><b>Chair:</b> <i>Rebecca Chandler (ISoP Vice-President, Coalition for Epidemic Preparedness Innovations, Sweden)</i>  <b>Co-Chairs:</b> <i>Gianmario Candore (Bayer, Germany) and Houda Sefiani (Moroccan Pharmacovigilance Centre, Rabat WHO Collaborating Centre, Morocco)</i></p>		
09:00	09:10	Welcome and Introduction
09:10	09:40	<b>Overview of study designs in pharmacoepidemiology</b> <i>Ylenia Ingrassiotta (University of Verona, Italy)</i>
09:40	10:10	<b>Essential statistics for pharmacoepidemiology</b> <i>Edward Burn (University of Oxford, UK)</i>
10:10	10:30	<b>Q&amp;A</b>
10:30	10:45	<b>Coffee break</b>
10:45	11:15	<b>Sources of error in pharmacoepidemiology</b> <i>Ersilia Lucenteforte (University of Pisa, Italy)</i>
11:15	11:45	<b>Overview of large health care databases</b> <i>Edward Burn (University of Oxford, UK)</i>

11:45	12:15	<b>Pharmacoepidemiology and its role within pharmacovigilance</b> <i>Samantha Lane (Drug Safety Research Unit (DSRU), UK)</i>
12:15	12:45	<b>Q&amp;A</b>
13:00	14:00	<b>Lunch / End of Course 2</b>

## Pre-Conference Course 3 13:30 – 17:00 Room T2

### Regulatory Updates across the Continuum of Spontaneous Reporting to Risk Minimization

This half-day course will address regulatory challenges and ‘state-of-the-art’ methodological approaches to current issues across the continuum of spontaneous reporting to risk minimization.

With a multi-region focus, learn about how the QPPV role has evolved to deal with increasingly complex pharmacovigilance regulations; hear from EMA speakers about the EU’s novel analytical methodologies in signal detection and risk assessment and methods for effectiveness evaluation of risk minimisation measures (RMMs); and learn about how Morocco is prioritizing multi-stakeholder involvement in risk management planning and implementation on a local level.

There will be plenty of time for Q&A and we look forward to lively discussion.

**Chairs:** *Deirdre McCarthy (ISoP Executive member, Gates MRI, USA) and Giampiero Mazzaglia (Milano Bicocca university, Italy)*

13:30	14:10	<b>QPPV Role: Insight and trends</b> <i>Barbara De Bernardi (Pfizer, Italy)</i>
14:10	14:50	<b>Novel analytical methodologies in signal management and risk assessment</b> <i>Cosimo Zaccaria (European Medicines Agency - EMA, Netherlands)</i> <i>(Virtual presentation)</i>
14:50	15:10	<b>Coffee break</b>
15:10	15:50	<b>Methods for effectiveness evaluation of risk minimisation measures (RMMs)</b> <i>Tomas Goedecke (European Medicines Agency - EMA, Netherlands)</i> <i>(Virtual presentation)</i>
15:50	16:30	<b>Importance of multi-stakeholder involvement in risk management planning and implementation</b> <i>Ghita Benabdallah (Centre Anti Poison et de Pharmacovigilance du Maroc (CAPM), Morocco)</i>
16:30	17:00	<b>Panel discussion and wrap-up</b>
19:30	21:00	<b>Welcome Reception – University of Verona, Cloister of San Francesco</b>

# CONFERENCE PROGRAMME

WEDNESDAY 21 SEPTEMBER 2022

08:00	08:30	<b>Registration</b>	<b>Polo Zanotto Main Entrance</b>
08:30	09:00	<b>1A0</b> <b>Opening session</b> <i>Mira Harrison-Woolrych (President of ISoP, New Zealand)</i> <i>Angela Caro Rojas (Scientific Chair ISoP 2022, Pontificia Universidad Javeriana, Colombia)</i> <i>Gianluca Trifirò (Local Chair ISoP 2022, University of Verona, Italy)</i> <i>Giorgio Racagni (President of the Italian Society of Pharmacology, Italy)</i> <i>Pierfrancesco Nocini (University of Verona, Italy)</i>	<b>Room T2/T3</b>
<b>Plenary Session 1A</b> <b>Lessons learned from COVID-19 pandemic</b> <i>Chairs: Gianluca Trifirò (ISoP Board member, University of Verona, Italy) and Achille P. Caputi (Emeritus Professor of the University of Messina, Italy)</i>			<b>09:00 – 10:30</b> <b>Room T2/T3</b>
09:00	09:30	<b>1A1:</b> <b>How post marketing drug/vaccine surveillance has been dealt with in Europe</b> <i>Bernard Bégaud (University of Bordeaux, France, and chair of the EPIPHARE scientific committee)</i>	
09:30	10:00	<b>1A2:</b> <b>COVID-19 pandemic: the experience of the Italian Drug Agency</b> <i>Patrizia Popoli (President of Scientific Technical Committee of the Italian Drug Agency, Italy)</i>	
10:00	10:30	<b>Q&amp;A / Panel discussion</b>	
10:30	11:00	<b>Coffee Break &amp; Poster viewing</b>	
<b>Plenary Session 1B</b> <b>Traditional and innovative approaches for post marketing surveillance of COVID-19 vaccines</b> <i>Chairs: Rebecca Chandler (ISoP Vice-President, Coalition for Epidemic Preparedness Innovations, Sweden), Evelina Tacconelli (University of Verona, Italy)</i>			<b>11:00 – 12:30</b> <b>Room T2/T3</b>
11:00	11:30	<b>1B1:</b> <b>A large distributed European database network for rapid COVID-19 vaccine surveillance</b> <i>Miriam Sturkenboom (University of Utrecht, Netherlands)</i>	
11:30	12:00	<b>1B2:</b> <b>Advancing the Science of Vaccine Safety: Introducing the International Network of Special Immunisation Services</b>	

*Karina Top (Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Canada)*

12:00 12:30 **Q&A / Panel discussion**

12:30 14:00 **Lunch Break & Flash Poster Presentations**

### Parallel session 1C

14:00 – 15:30  
Room T2

**PV of Biotechnology drugs: from Advanced Therapy medicine products to biosimilars**

*Chairs: Qun-Ying Yue (Chair of the Pharmacogenomics SIG, Uppsala Monitoring Centre, Sweden) and Annalisa Capuano (PRAC Member - University of Campania Luigi Vanvitelli, Italy)*

14:00 14:30 **1C1:**  
**Interchangeability between originators and biosimilars: Clinical and methodological considerations**  
*Thijs Giezen (EMA Biosimilar working party, Netherlands)*

14:30 15:00 **1C2:**  
**Large scale research network for biologic post marketing surveillance in Italy**  
*Ylenia Ingrasciotta (University of Verona, Italy)*

15:00 15:10 **1C3 (Abstract Presentation)**  
**O-001**  
**Effectiveness and Tolerance of Biotherapy in the Treatment of Chronic Inflammatory Diseases and Rheumatism in children**  
*Rania Mourchid (Mohammed V University, Morocco)*

15:10 15:20 **1C4 (Abstract Presentation)**  
**O-002**  
**European Pharmacovigilance Analysis of Cardiac Arrhythmias Events with Immune Checkpoint Inhibitors**  
*Annamaria Mascolo (University of Campania Luigi Vanvitelli, Italy)*

### Parallel session 1D

14:00 – 15:30  
Room T3

**Strategies to prevent Medication errors: new approaches**

*Chairs: Brian Edwards (Chair of the Medication Error SIG, Husoteria Ltd, UK) and Angela Caro Rojas (Pontificia Universidad Javeriana, Colombia)*

**1D1:**  
**ECAMET Alliance: Patient Safety Project experience**  
*Alix Bullman (ECAMET Alliance, Belgium)*

**1D2:**  
**Interaction between the Institute for Safe Medication Practices (ISMP) and ISoP**  
*Rita Jew (Institute for Safe Medication Practices (ISMP), USA)*

**1D3 (Abstract Presentation)**  
**O-003**  
**Potentially Inappropriate Medication in Older Adult's Adverse Drug Reactions Spontaneous Reports**  
*Fátima Roque (Research Unit for Inland Development, Polytechnic of Guarda (UDI-IPG), Portugal)*

**1D4 (Abstract Presentation)**  
**O-004**  
**Analysis of Medication Errors in Children and Adolescents Reported to HALMED**  
*Morana Pavičić (HALMED, Croatia)*

15:20	15:30	Q&A	Q&A
15:30	16:00	Coffee Break & Poster viewing	
<b>Parallel session 1E</b>			<b>Parallel session 1F</b>
16:00 – 17:30 Room T2			16:00 – 17:30 Room T3
<b>How to communicate risk in crisis?</b> <i>Chairs: Priya Bahri (Chair of the Risk Communication SIG, Netherlands) and Ulrich Hagemann (ISoP, Germany)</i>			<b>Medicines for Women: Global Challenges and Initiatives</b> <i>Chairs: Mira Harrison-Woolrych (President of ISoP, Chair of the Women's Medicines SIG, New Zealand) and Brian Edwards (Chair of the Medication Error SIG, Husoteria Ltd, UK)</i>
16:00	16:10	<b>Introduction with examples of various crisis scenarios in pharmacovigilance</b> <i>Priya Bahri (Chair of the Risk Communication SIG, Netherlands)</i>	16:00 16:10 <b>Welcome and Introduction to the session and to the ISoP Women's Medicines SIG</b> <i>Mira Harrison-Woolrych (President of ISoP, Chair of the Women's Medicines SIG, New Zealand)</i>
16:10	16:30	<b>1E1:</b> <b>How do regulatory decisions relate to public health decisions? Communicating about Dengvaxia in the Philippines between science and emotions</b> <i>Kenneth Hartigan-Go (Asian Institute of Management, Philippines)</i>	16:10 16:40 <b>1F1:</b> <b>Pregnant women in clinical trials: ethical, scientific and safety aspects</b> <i>Katarina Ilic (Takeda, USA)</i>
16:30	17:00	<b>1E2:</b> <b>How do local contexts relate to public health communication? - Communicating about COVID-19 vaccines in Italy and the Netherlands</b> <i>Marco Tuccori (University Hospital of Pisa, Italy) and Agnes Kant (The Netherlands Pharmacovigilance Centre Lareb)</i>	16:40 16:50 <b>1F2 (Abstract Presentation)</b> <b>O-007</b> <b>Impact of the 2018 Pregnancy Prevention Program on the Use of Oral Retinoids in Childbearing Age Females in Europe</b> <i>Carlos Durán (University Medical Center Utrecht, Netherlands)</i>
17:00	17:10	<b>1E3 (Abstract Presentation)</b> <b>O-005</b> <b>Animated Explainer Videos as an Effective Way to Communicate Statistical Methods in Pharmacovigilance</b> <i>Eva-Lisa Meldau (Uppsala Monitoring Centre, Sweden)</i>	16:50 17:20 <b>1F3:</b> <b>COVID-19 vaccines and menstrual disorders</b> <i>Birgitta Grundmark (Norwegian Medicines Agency, Norway)</i>

17:10	17:20	<b>1E4 (Abstract Presentation)</b> <b>O-006</b> <b>Visual Communication of Safety Data in Ongoing Studies: The Adaptive Benefit-Risk Assessment tool for Clinical Trials (ABRA-CTV)</b> <i>Christopher T. Bond (Bristol Myers Squibb, USA)</i>	17:20	17:30	<b>Discussion</b>	
17:20	17:30	<b>Discussion moderated by Co-Chair Ulrich Hagemann and Wrap-up</b> <i>Chair: Priya Bahri (Chair of the Risk Communication SIG, Netherlands)</i>				
18:00	19:30	<b>Student Meet and Greet</b>				<b>Cloister of San Francesco</b>
18:00	19:00	<b>ISoP Special Interest Groups (SIGs) Meetings</b> 1. Medication errors 2. Risk Communication 3. Vaccines 4. EcoPV				Room 1.4 Room S8 Room S9 Room T1

# THURSDAY 22 SEPTEMBER 2022

<b>Plenary Session 2A</b>			<b>08:30 – 10:10</b> <b>Room T2/T3</b>	
<b>Big Data for PV - are we delivering on the promises?</b> <i>Chairs: Gianmario Candore (Bayer, Germany) and Deirdre McCarthy (ISoP EC member, Gates MRI, USA)</i>				
08:30	09:00	<b>2A1:</b> <b>Big data vs. smart data for post-marketing surveillance of drugs/vaccines</b> <i>Gianluca Trifirò (University of Verona, Italy)</i>		
09:00	09:30	<b>2A2:</b> <b>How big data support post marketing surveillance in USA: the Sentinel initiative</b> <i>Darren Toh (Harvard Medical School and Harvard Pilgrim Health Care Institute, USA)</i>		
09:30	10:00	<b>2A3:</b> <b>Data Analysis and Real World Interrogation Network (DARWIN EU®)</b> <i>Andrej Segec (European Medicines Agency – EMA, Netherlands)</i>		
10:00	10:10	<b>Q&amp;A</b>		
10:10	10:40	<b>Coffee Break &amp; Poster viewing</b>		
<b>Parallel session 2B</b>		<b>10:40 – 12:00</b> <b>Room T2/T3</b>	<b>Parallel session 2C</b>	
			<b>10:40 – 12:00</b> <b>Room T1</b>	
<b>AI/Machine learning for drug safety signal detection in PV: where do we stand?</b> <i>Chairs: Antoine Pariente (University of Bordeaux, France) and Rosa Gini (Agenzia regionale di sanità della Toscana, Italy)</i>			<b>Interaction between Pharmacovigilance and Clinical Practice</b> <i>Chairs: Mónica Tarapués (Central University of Ecuador) and Birgitta Grundmark (Norwegian Medicines Agency, Norway)</i>	
10:40	11:05	<b>2B1:</b> <b>Current status of machine learning across the pharmacovigilance lifecycle: A systematic review</b> <i>Andrew Bate (GSK, UK)</i>	<b>2C1:</b> <b>The potential contributions of pharmacovigilance to healthy medical prescribing</b> <i>Joan Ramon Laporte (Autonomous University of Barcelona, Spain)</i>	
11:05	11:30	<b>2B2:</b> <b>AI/Machine learning for drug safety signal detection in PV: where do we stand? The perspective of a public pharmacovigilance center</b> <i>Antoine Pariente (University of Bordeaux, France)</i>	<b>2C2:</b> <b>Do we really understand what happened? – Reflections on case assessment</b> <i>Eugene Van Puijenbroek (The Netherlands Pharmacovigilance Centre Lareb)</i>	



11:30	11:40	<b>2B3</b> (Abstract Presentation) <b>O-008</b> <b>Performance of an Artificial Intelligence System Tool for the Detection of ADRs from Patients' Reports During the Covid-19 Vaccination Campaign</b> <i>Guillaume Louis Martin (Synapse Medicine, France)</i>	<b>2C3</b> (Abstract Presentation) <b>O-010</b> <b>Search for Additional Cases in Electronic Health Records (EHRs) to Strengthen Potential Signals from Spontaneous Reporting</b> <i>Agnes Kant (The Netherlands Pharmacovigilance Centre Lareb)</i>
11:40	11:50	<b>2B4</b> (Abstract Presentation) <b>O-009</b> <b>Investigating Hidden Networks in Spontaneous Reporting Systems</b> <i>Michele Fusaroli (University of Bologna, Italy)</i>	<b>2C4</b> (Abstract Presentation) <b>O-011</b> <b>Do Monitored Dosage Systems Increase Risk for Patients' Safe Discharge from Hospital? A Retrospective Analysis of Pharmacists' Interventions</b> <i>Leeanne Stewart (University of Birmingham, UK)</i>
11:50	12:00	<b>Q&amp;A</b>	<b>Q&amp;A</b>
12:00	13:00	<b>Lunch Break &amp; Flash Poster Presentations</b>	

## 2D: ISoP General Assembly

Committed to safer use of medicines worldwide

*Chairs: Mira Harrison-Woolrych (President of ISoP, New Zealand) and Deirdre McCarthy (Secretary General, Gates MRI, USA)*

13:00 – 14:30

Room T2/T3

### Agenda

- |  |  |
|--|--|
| 1. Welcome, introductions, housekeeping      | 9. Financial Report                            |
| 2. Tribute to Sten Olsson                    | 10. Report from Chapters                       |
| 3. Approval of Agenda                        | 11. Report on SIGs                             |
| 4. Approval of Minutes GA 2021               | 12. Fellowship and Honorary Member Awards 2022 |
| 5. President's overview of ISoP activities   | 13. Advisory Board election results            |
| 6. Report from the new ISoP Scientific Board | 14. Looking forward                            |
| 7. By-law updates                            | 15. AoB and Q&A                                |
| 8. Membership Report                         |  |

14:30 15:00 **Coffee Break & Poster viewing**

## 2E: Global Pharmacovigilance: Hot topics

*Chairs: Mónica Tarapué (Central University of Ecuador) and Angela Caro Rojas (Pontificia Universidad Javeriana, Colombia)*

15:00 – 17:30

Room T2/T3

15:00 15:45 **2E1:**  
**SIGs & Chapters highlights**

15:45 17:30 **2E2:**  
**Abstract presentations**

**2E2.1 – O-012:**

**Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase® Data and Evidence from Real World**

*Marco Bonaso (University of Pisa, Italy)*

**2E2.2 - O-013:**

**Risk of Glaucoma Diagnosis in Patients Who Received Intravitreal Injections of VEGF Inhibitors: a Cohort Study**

*Andrea Spini (Azienda Ospedaliera Universitaria Senese, Italy)*

**2E2.3 - O-014:**

**A Revised Time-to-onset Signal Detection algorithm in the Context of Mass Vaccination**

*Lionel Van Holle (OpenSourcePV, Belgium)*

**2E2.4 - O-015:**

**Adverse Events to COVID-19 Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries**

*Comfort Ogar (WHO, Nigeria)*

*(Virtual presentation)*

**2E2.5 - O-016:**

**Factors Associated with Hospital Death in Patients with Adverse Drug Events in Brazil, from 2011 to 2020**

*Paulo Sérgio Dourado Arrais (Universidade Federal do Ceará, Brazil)*

**2E2.6 - O-017:**

**Effectiveness and Safety of Maintenance Immunosuppressive Drug Therapies in Kidney Transplant: A Real-World Retrospective Cohort Study in Italy**

*Marco Finocchietti (ASL Roma 1, Italy)*

**2E2.7 - O-018:**

**Are COVID-19 Vaccines Safe in Children? Comparative Analysis of European Web-Based Prospective Monitoring vs. Pivotal Trials**

*Nicoletta Luxi (University of Verona, Italy)*

**2E2.8 - O-019:**

**The Risk of Oligospermia with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases**

*Luis Velez-Nandayapa (University of Basel / Novartis, Switzerland)*

**2E2.9 - O-020:**

**Perception and Utilization of Skin Lightening Agents Among Females of Asmara City: A Lesson for Strengthening Cosmetovigilance**

*Mulugeta Russom (Ministry of Health, Eritrea)*

**2E2.10 - O-021:**

**Drug-related Hospital Admissions in Paediatrics – Is There Potential for Prevention?**

*Irmgard Toni (Universitätsklinikum Erlangen, Germany)*

19:30 22:00

**Conference Dinner – Giardino e Palazzo dei Conti Giusti**

# FRIDAY 23 SEPTEMBER 2022

Parallel session 3A		09:00 – 10:30 Room T1	Parallel session 3B		09:00 – 10:30 Room T2/T3
<b>Training and Professional framework of PV</b> <i>Chairs: Linda Härmark (The Netherlands Pharmacovigilance Centre Lareb) and Jan Petracek (Institute of Pharmacovigilance, Czech Republic)</i>			<b>Herbal and Traditional Medicines PV Advances</b> <i>Chairs: Souad Skalli (Chair of ISoP Herbal and Traditional Medicines SIG, Mohammed V University, Morocco) and Francesca Menniti Ippolito (Italian National Health Institute and Chair of herbal remedies monitoring in Italy)</i>		
09:00	09:20	<b>3A1:</b> <b>PV specialist professional development</b> <i>Jan Petracek (Institute of Pharmacovigilance, Czech Republic)</i>	09:00	09:30	<b>3B1:</b> <b>Restructuring of the University Curriculum by Introducing the Teaching of Phytovigilance: Importance or even Urgency</b> <i>Souad Skalli (Chair of ISoP Herbal and Traditional Medicines SIG, Mohammed V University, Morocco)</i>
09:20	09:40	<b>3A2:</b> <b>The Eu2P experience</b> <i>Francesco Salvo (University of Bordeaux, France)</i>	09:30	10:00	<b>3B2:</b> <b>Introductory remarks/ Food supplements vigilance systems in a public health perspective: the European context</b> <i>Francesca Menniti Ippolito (Italian National Health Institute and chair of Herbal Remedies Monitoring, Italy)</i>
09:40	10:00	<b>3A3:</b> <b>Pharmacovigilance training for health care professionals</b> <i>Linda Härmark (The Netherlands Pharmacovigilance Centre Lareb)</i>	10:00	10:10	<b>3B3 (Abstract Presentation) O-024</b> <b>Recommended Best Practices of Pharmacovigilance of Herbal Medicinal Products</b> <i>Florence Van Hunsel (The Netherlands Pharmacovigilance Centre Lareb, Netherlands)</i>
10:00	10:10	<b>3A4 (Abstract Presentation) O-022</b> <b>Development and Evaluation of a Blended Pharmacovigilance e-Learning Course in Africa</b> <i>Lara Magro (University of Verona, Italy)</i>	10:10	10:20	<b>3B4 (Abstract Presentation) O-025</b> <b>Safety of Medical Cannabis: A Descriptive Study using the Quebec Cannabis Registry</b>
10:10	10:20	<b>3A5 (Abstract Presentation) O-023</b> <b>Teaching Pharmacovigilance to French Medical Students during the Covid-19 Pandemic: Interest of</b>			

		<b>Distance Learning Clinical Reasoning Sessions</b> <i>François Montastruc (Toulouse University Hospital, France)</i>			<i>Yola Moride (YolaRX Consultants, Canada)</i>
10:20	10:30	<b>Q&amp;A</b>	10:20	10:30	<b>Q&amp;A</b>
10:30	11:00	<b>Coffee Break</b>			
<b>3C: Lecture in memory of Prof. Giampaolo Velo</b>					<b>11:00 – 11:50</b>
<i>Chair: Roberto Leone (University of Verona, Italy)</i>					<b>Room T2/T3</b>
11:00	11:05	<b>3C1: Introduction</b> <i>Roberto Leone (University of Verona, Italy)</i>			
11:05	11:20	<b>3C2: Remembering Giampaolo Velo</b> <i>Ralph Edwards (former Director of the Uppsala Monitoring Centre, Sweden)</i>			
11:20	11:50	<b>3C3: EcoPharmacovigilance: challenges and opportunities</b> <i>John Wilkinson (University of York, UK)</i>			
<b>3D: Bengt Erik Wiholm Lecture</b>					<b>11:50 – 12:25</b>
<i>Chair: Mira Harrison-Woolrych (President of ISoP, New Zealand)</i>					<b>Room T2/T3</b>
11:50	11:55	<b>3D1: Introduction</b> <i>Mira Harrison-Woolrych (President of ISoP, New Zealand)</i>			
11:55	12:25	<b>3D2: Pharmacovigilance: where we are, where we came from and where we are going</b> <i>Saad Shakir (Drug Safety Research Unit, UK)</i>			
<b>3E: Closing Ceremony</b>					<b>12:25 – 13:00</b>
<i>Chairs: Mira Harrison-Woolrych (President of ISoP, New Zealand)</i> <i>Angela Caro Rojas (Scientific Chair ISoP 2022, Pontificia Universidad Javeriana, Colombia)</i> <i>Gianluca Trifirò (Local Chair ISoP 2022, University of Verona, Italy)</i>					<b>Room T2/T3</b>
12:25	12:35	<b>3E1: Poster Prize Awards</b> <b>Poster Prize Committee:</b> <i>Ghita Benabdallah (Chair)(Centre Anti Poison et de Pharmacovigilance du Maroc (CAPM), Morocco), Helaine Carneiro Capucho (Brazilian Health Regulatory Agency - ANVISA, Brazil), Ylenia Ingrassiotta (University of Verona, Italy)</i>			
12:35	12:45	<b>3E2: Host presentation for ISoP 2023</b>			
12:45	13:00	<b>3E3: Final remarks and closure</b>			
13:00	14:00	<b>Light Lunch</b>			